GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA

Promising phase Ib results for velzatinib* (IDRX-42) support accelerating start of phase III trial in 1L gastrointestinal stromal tumours (GIST) New Blenrep (belantamab mafodotin) results will highlight potential for long-term efficacy in relapsed or refractory multiple myeloma and meaningful activity in newly diagnosed patients Modelling data predict cure rate with Jemperli (dostarlimab) plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer New analyses will show Ojjaara/Omjjara (momelotinib) delivers benefit across patient subgroups including when switching from ruxolitinib GSK plc (LSE/NYSE: GSK) will present new data from its expanding oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (29 May - 2 June) in Chicago, IL and the 31st European Hematology Association (EHA) Congress (11 - 14 June) in Stockholm, Sweden. These findings demonstrate long-term outcomes for current therapies and pipeline expansion into additional tumour types and earlier treatment lines to advance practice-changing medicines for people with cancer. First results for velzatinib in first-line (1L) advanced gastrointestinal stromal tumours (GIST) will show promising activity and tolerability across KIT mutations. These data have accelerated initiation of the StrateGIST Frontline phase III clinical trial given the need for therapies in 1L that broadly inhibit clinically relevant KIT variants, a key driver of relapse today. Data for velzatinib across clinically relevant KIT mutations in all lines, including 1L and second-line (2L) advanced GIST, will show encouraging anti-tumour activity and tolerability supporting the potential for a differentiated clinical profile (ASCO oral presentation abstract #11501). Analyses of velzatinib will show broad activity and substantial circulating tumour DNA (ctDNA) clearance of clinically meaningful KIT mutations and inhibition of GIST tumour cells (ASCO rapid oral presentation abstract #11520). New DREAMM clinical trial programme data will show durable benefit with belantamab mafodotin combinations in relapsed or refractory multiple myeloma (RRMM) and potential in newly diagnosed multiple myeloma Four-year results from DREAMM-7 will show long-term efficacy, including overall survival, depth of response and health-related quality of life, reinforcing belantamab mafodotin with bortezomib and dexamethasone as a potential new standard of care in RRMM (EHA abstract #PS1862). DREAMM-8 long-term responder and sustained minimal residual disease negativity analyses will show depth and durability of response for patients treated with belantamab mafodotin in combination with pomalidomide and dexamethasone in RRMM (ASCO abstract #7565 and rapid oral presentation abstract #7515). In transplant-ineligible newly diagnosed multiple myeloma patients, final DREAMM-9 analysis will provide clinical evidence of meaningful activity with an optimised induction/maintenance dosing strategy of belantamab mafodotin (ASCO oral presentation abstract #7503). Latest modelling data will predict the cure rate with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer, supporting patient care New long-term analyses from the phase III RUBY trial will reinforce the sustained benefit of dostarlimab plus chemotherapy in patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer. Building from these results, new modelling analyses predict the proportion of patients who may be considered “cured”—defined as those who survive their disease and no longer experience disease-related mortality. These data complement traditional clinical trial measures, such as progression-free and overall survival, to support clinicians in advising their patients on treatment options and potential outcomes (ASCO oral presentation abstract #5501). New analyses will show momelotinib can deliver symptom control across myelofibrosis patient subgroups and when switching from ruxolitinib Post-hoc analyses from SIMPLIFY-1 and MOMENTUM will further build evidence for momelotinib across patient risk profiles in myelofibrosis, demonstrating consistent spleen, symptom and anaemia responses. Data will show earlier initiation of treatment before progression may be associated with better outcomes, underscoring the importance of initiating treatment before progression (EHA abstract #PS1995). New analyses from SIMPLIFY-1 and SIMPLIFY-2 will show that most patients in the trials could transition directly from ruxolitinib to momelotinib without acute symptom worsening. Symptoms remained stable or improved in the majority of patients. These data address a key challenge in treatment sequencing (EHA abstract #PS2001).

The release as fetched from its publisher. gsk.com ↗